Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25793375 | 0.91 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL25793365 | 0.89 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL25286547 | 0.87 | BRAF (0.39) | — | |
| SCHEMBL25793371 | 0.85 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL20587522 | 0.82 | ROCK2 (0.36) | DGAT1 | |
| SCHEMBL29821567 | 0.82 | ROCK2 (0.36) | DGAT1 | |
| SCHEMBL25793364 | 0.82 | MET (0.34) | DGAT1 | |
| SCHEMBL25793118 | 0.81 | KDR (0.42) | DGAT1 | |
| SCHEMBL30486130 | 0.81 | KDR (0.42) | DGAT1 | |
| SCHEMBL4246766 | 0.81 | AXL (0.38) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | DGAT1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.